GAM
PVLA

Gotham Asset Management’s Palvella Therapeutics PVLA Stock Holding History

Gotham Asset Management’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-458
Closed -$250K – 1064
2018
Q1 		$250K Buy
+458
New +$284K ﹤0.01% 854

Other funds holding PVLA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Gotham Asset Management's PVLA Position: Q2 2018 in Review

Gotham Asset Management sold out of Palvella Therapeutics (PVLA) in Q2 2018, closing a stake of 458 shares — an estimated $250K sold.

Gotham Asset Management first reported a position in PVLA in Q1 2018 and held it in 1 quarter. The position peaked at $250K in Q1 2018. 115 funds tracked by Wall St. Rank hold PVLA as of Q2 2018.

  • Gotham Asset Management reported no remaining Palvella Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Gotham Asset Management sold 458 Palvella Therapeutics shares in Q2 2018, an estimated $250K.
  • Gotham Asset Management first reported a position in Palvella Therapeutics in Q1 2018 and held it in 1 quarter.
  • Gotham Asset Management's Palvella Therapeutics position peaked at $250K in Q1 2018.
  • 115 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2018.

Based on Gotham Asset Management's 13F filing for Q2 2018, filed 14 Aug 2018.